ISSN 1673-3770 CN 37-1437/R
山东大学耳鼻喉眼学报 ›› 2017, Vol. 31 ›› Issue (3): 4-8.doi: 10.6040/j.issn.1673-3770.0.2017.138
许昱,陶泽璋
XU Yu， TAO Zezhang
摘要： 变应性鼻炎的发病率逐年增高,给患者生活质量带来严重影响。药物治疗是变应性鼻炎控制症状主要手段,相关药物各有特点。在进行药物治疗时应遵循规范性和个体化的原则,根据患者主要症状及症状严重程度合理用药,并根据疗效和不良反应情况适时进行药物的升级和降级。
中图分类号:
| [1] Wang XD, Zheng M, Lou HF, et al. An increased prevalence of self-reported allergic rhinitis in major Chinese cities from 2005 to 2011[J]. Allergy, 2016, 71(8):1170-1180. [2] Juniper EF, Guyatt GH, O'Byrne PM, et al. Aqueous beclomethasonediproprionate nasal spray: regular versus “as required” use in the treatment of seasonal allergic rhinitis[J]. J Allergy Clin Immunol, 1990, 86(3):380-386. [3] Juniper EF, Guyatt GH, Archer B, et al. Aqueous beclomethasonedipropionate in the treatment of ragweed pollen-induced rhinitis: further exploration of “as needed” use[J]. J Allergy Clin Immunol, 1993, 92(1 Pt 1):66-67. [4] Dykewicz MS, Kaiser HB, Nathan RA, et al. Fluticasone propionate aqueous nasal spray improves nasal symptoms of seasonal allergic rhinitis when used as needed(prn)[J]. Ann Allergy Asthma Immunol, 2003, 91(1):44-48. [5] Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials[J]. BMJ, 1998, 317(7173):1624-1629. [6] Yá(~overn)ez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis[J]. Ann Allergy Asthma Immunol, 2002, 89(5):479-484. [7] Benninger M, Farrar JR, Blaiss M, et al. Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class[J]. Ann Allergy Asthma Immunol, 2010, 104(1):13-29. [8] Wilson AM, O'Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis[J]. Am J Med, 2004, 116(5):338-344. [9] Bielory L, Chun Y, Bielory BP, et al. Impact of mometasonefuroate nasal spray on individual ocular symptoms of allergic rhinitis: a meta-analysis[J]. Allergy, 2011, 66(5):686-693. [10] Lohia S, Schlosser RJ, Soler ZM. Impact of intranasal corticosteroids on asthmaoutcomes in allergic rhinitis: a meta-analysis[J]. Allergy, 2013, 68(5):569-579. [11] Ratner PH, Meltzer EO, Teper A. Mometasonefuroate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis[J]. Int J Pediatr Otorhinolaryngol, 2009, 73(5):651-657. [12] Allen DB, Meltzer EO, Jr LR, et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year[J]. Allergy Asthma Proc, 2002, 23(6):407-413. [13] Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasonefuroate aqueous nasal spray[J]. Pediatrics, 2000, 105(2):E22. [14] Karaki M, Akiyama K, Mori N. Efficacy of intranasal steroid spray(mometasonefuroate)on treatment of patients with seasonal allergic rhinitis: comparison with oral corticosteroids[J]. Auris Nasus Larynx, 2013, 40(3):277-281. [15] Simons FE. Advances in H1-antihistamines[J]. New Eng J Med, 2004, 351(21):2203-2217. [16] Dizdar EA, Sekerel BE, Keskin O, et al. The effect of regular versus on-demand desloratadine treatment in children with allergic rhinitis[J]. Int J Pediatr Otorhinolaryngol, 2007, 71(6):843-849. [17] Laekeman G, Simoens S, Buffels J, et al. Continuous versus on-demand pharmacotherapy of allergic rhinitis: evidence and practice[J]. Respir Med, 2010, 4(5):615-625. [18] Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: allergic rhinitis[J]. Otolaryngol Head Neck Surg, 2015, 152(Suppl 1):S1-S43. [19] Horak F, Zieglmayer UP, Zieglmayer R, et al. Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy[J]. Curr Med Res Opin, 2006, 22(1):151-157. [20] Kaliner MA, Berger WE, Ratner PH, et al. The efficacy of intranasal antihistamines in the treatment of allergic rhinitis[J]. Allergy Asthma Immunol, 2011, 106(Suppl 2):S6-S11. [21] Laforce CF, Corren J, Wheeler WJ, et al. Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadine[J]. Ann Allergy Asthma Immunol, 2004, 93(2):154-159. [22] Kaliner MA. Azelastine and olopatadine in the treatment of allergic rhinitis[J]. Ann Allergy Asthma Immunol, 2009, 103(5):373-380. [23] Carr WW, Ratner P, Munzel U, et al. Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis[J]. Allergy Asthma Proc, 2012, 33(6):450-458. [24] Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: an evidence-based review[J]. Drugs, 2007, 67(6):887-901. [25] Van AJ, Philip G, Pedinoff AJ, et al. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period[J]. Allergy, 2003, 58(58):1268-1276. [26] Bisgaard H, Skoner D, Boza ML, et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions[J]. Pediatr Pulmonol, 2009, 44(6):568-579. [27] Mösges R, Klimek L. Todays allergic rhinitis patients are different: new factors that may play a role[J]. Allergy, 2007, 62(9):969-975. [28] Anolik R. Clinical benefits of combination treatment with mometasonefuroate nasal spray and loratadinevsmonotherapy with mometasonefuroate in the treatment of seasonal allergic rhinitis[J]. Ann Allergy Asthma Immunol, 2008, 100(3):264-271. [29] Can D, Tanaç R, Demir E, et al. Is the usage of intranasal glucocorticosteroids alone in allergic rhinitis sufficient?[J]. Allergy Asthma Proc, 2006, 27(3):248-253. [30] Nasser M, Fedorowicz Z, Aljufairi H, et al. Antihistamines used in addition to topical nasal steroids for intermittent and persistent allergic rhinitis in children[J]. Cochrane Database Syst Rev, 2010, 7(7):CD006989. [31] Hilberg O. Effect of terfenadine and budesonide on nasal symptoms, olfaction, and nasal airway patency following allergen challenge[J]. Allergy, 1995, 50(8):683-688. [32] Ratner PH, Hampel F, Bavel JV, et al. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis[J]. Ann Allergy Asthma Immunol, 2008, 100(1):74-81. [33] Hampel FC, Ratner PH, Van BJ, et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device[J]. Ann Allergy Asthma Immunol, 2010, 105(2):168-173. [34] Laforce CF, Carr W, Tilles SA, et al. Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination with an intranasal corticosteroid in seasonal allergic rhinitis[J]. Allergy Asthma Proc, 2010, 31(2):132-140. [35] Carr W, Bernstein J, Lieberman P, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis[J]. J Allergy Clin Immunol, 2012, 129(129):1282-1289.e10. [36] Rael EL, Ramey J, Lockey RF. Oxymetazoline hydrochloride combined with mometasone nasal spray for persistent nasal congestion(pilot study)[J]. World Allergy Organ J, 2011, 4(3):65-67. [37] Meltzer EO, Bernstein DI, Prenner BM, et al. Mometasonefuroate nasal spray plus oxymetazoline nasal spray: short-term efficacy and safety in seasonal allergic rhinitis[J]. Am J Rhinol Allergy, 2013, 27(2):102-108. [38] Cingi C, Gunhan K, Gage-White L, et al. Efficacy of leukotriene antagonists as concomitant therapy in allergic rhinitis[J]. Laryngoscope, 2010, 120(9):1718-1723. [39] Rodrigo GJ, Ya(~overn)ez A. The role of antileukotriene therapy in seasonal allergic rhinitis: a systematic review of randomized trials[J]. Ann Allergy Asthma Immunol, 2006, 96(6):779-786. [40] Lu S, Malice MP, Dass SB, et al. Clinical studies of combination montelukast and loratadine in patients with seasonal allergic rhinitis.[J]. J Asthma, 2009, 46(9):878-883. [41] Nayak AS, Philip G, Lu S, et al. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall[J]. Ann Allergy Asthma Immunol, 2002, 88(6):592-600. [42] Esteitie R, Detineo M, Naclerio RM, et al. Effect of the addition of montelukast to fluticasone propionate for the treatment of perennial allergic rhinitis[J]. Ann Allergy Asthma Immunol, 2010, 105(2):155-161. [43] Goh BS, Ismail MI, Husain S. Quality of life assessment in patients with moderate to severe allergic rhinitis treated with montelukast and/or intranasal steroids: a randomised, double-blind, placebo-controlled study[J]. J Laryngol Otol, 2014, 128(3):242-248. [44] 中华医学会耳鼻咽喉头颈外科学分会鼻科学组. 变应性鼻炎诊断和治疗指南(2015年,天津)[J]. 中华耳鼻咽喉头颈外科杂志, 2016, 51(1):6-24. Subspecialty Group of Rhinology, Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery; Subspecialty Group of Rhinology, Society of Otorhinolaryngology Head and Neck Surgery, Chinese Medical Association. Chinese guidelines for diagnosis and treatment of allergic rhinitis[J]. Chin J Otorhinolaryngol Head Neck Surg, 2016, 51(1):6-24. [45] Meltzer EO. Pharmacotherapeutic strategies for allergic rhinitis: matching treatment to symptoms, disease progression, and associated conditions.[J]. Allergy Asthma Proceed, 2013, 34(4):301-311. [46] Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma(ARIA)2008 update(in collaboration with the World Health Organization, GA(2)LEN and AllerGen)[J]. Allergy, 2008, 63(Suppl 86):8-160. |
| [1] | 王坛,武珂,李连庆,宫丽丽. 皮下免疫治疗注射后出现全身不良反应的伴发因素及处理[J]. 山东大学耳鼻喉眼学报, 2018, 32(5): 71-74. |
| [2] | 卢汉桂,林歆胜,姚丹勉,魏永新,李创伟. 变应性鼻炎大鼠IL-35的表达及对辅助性T细胞免疫调节的影响[J]. 山东大学耳鼻喉眼学报, 2018, 32(5): 66-70. |
| [3] | 浦洪波,杜晓东. 无锡地区2 000例变应性鼻炎变应原检测结果分析[J]. 山东大学耳鼻喉眼学报, 2018, 32(4): 105-107. |
| [4] | 代亚错,李靖,万保罗,臧艳姿,黄颖铭. 个体化治疗咽喉部海绵状血管瘤二例[J]. 山东大学耳鼻喉眼学报, 2018, 32(4): 110-112. |
| [5] | 陈鸣,俞雪飞. 浅谈伴有变应性鼻炎的慢性鼻窦炎的治疗[J]. 山东大学耳鼻喉眼学报, 2018, 32(3): 18-22. |
| [6] | 吴湘萍. 患者管理方式对变应性鼻炎舌下含服粉尘螨滴剂疗效的影响[J]. 山东大学耳鼻喉眼学报, 2018, 32(3): 68-72. |
| [7] | 李松,王宗贵,杨景朴,张竹萍. 鼻内镜下翼管神经切断术进展[J]. 山东大学耳鼻喉眼学报, 2018, 32(1): 72-76. |
| [8] | 郅莉莉,宋道亮. 嗜酸性粒细胞及IL5在上颌窦后鼻孔息肉与鼻息肉中表达的差异[J]. 山东大学耳鼻喉眼学报, 2017, 31(4): 43-46. |
| [9] | 万文锦,王文,程雷. 尘螨变应性鼻炎皮下免疫治疗与舌下免疫治疗的荟萃分析[J]. 山东大学耳鼻喉眼学报, 2017, 31(4): 103-108. |
| [10] | 朱新华. 变应性鼻炎冲击免疫治疗的临床应用[J]. 山东大学耳鼻喉眼学报, 2017, 31(3): 13-17. |
| [11] | 史丽,赵莉,张红萍. 变应性鼻炎的长期抗炎治疗[J]. 山东大学耳鼻喉眼学报, 2017, 31(3): 9-12. |
| [12] | 刘静. 基于整体观念变应性鼻炎的中医辨证论治[J]. 山东大学耳鼻喉眼学报, 2017, 31(3): 28-30. |
| [13] | 程雷,钱俊俊,田慧琴. 变应性鼻炎研究的若干进展[J]. 山东大学耳鼻喉眼学报, 2017, 31(3): 1-3. |
| [14] | 刘英,叶小静,赵春丽,季青,黄谦. 季节性变应性鼻炎预防性治疗观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(3): 37-40. |
| [15] | 李莉珠,吴卿,易欣,田理. 变应性鼻炎中医证候动物模型的研究进展[J]. 山东大学耳鼻喉眼学报, 2017, 31(3): 60-63. |
|